Pillstats
Rx only · Injection · Subcutaneous

Sumatriptan

Brands: Imitrex · Sumatriptan Succinate

4 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US6 NDCs
4 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCN02CC01
RxCUI (US)37418
US makers4 labelers
Packages10
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$99.01$198.03$297.04$396.05Dec 2025Apr 2026Jul 2026
$344.105
Latest avg · Jul 22, 2026
+13%
Since Dec 17, 2025
4
Active US suppliers
70%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

4509001.4K1.8K2025 Q12025 Q22025 Q32025 Q42026 Q1
1.1K
Rx · 2026 Q1
2.9K
Units dispensed
-31%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it4 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
GlaxoSmithKline LLCunknown4SUPPLYING
Baxter Healthcare Corporationunknown3SUPPLYING
Hikma Pharmaceuticals USA Inc.unknown2SUPPLYING
A-S Medication Solutionsunknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Nov 6, 2013
    RECALLRecall (Class II): Imitrex STATdose System, Imitrex (sumatriptan succinate) Injection, 2 prefilled 0.5 mL syringe cartridges each containi…

    Lack of Assurance of Sterility: A small number of pre-filled syringes may contain needles which protrude through the needle shield. — Recalling firm: GlaxoSmithKline, LLC. — Nationwide